Lot-to-Lot Variability

Lot-to-lot variability is the shift in results that can appear when one production lot of a reagent, calibrator or kit replaces another. Each lot is made from different raw-material lots, sometimes on different equipment or by different people, so small differences in concentration, activity or matrix are expected. The question is whether the difference stays inside limits that do not affect the use of the result.

Manufacturers control it upstream: raw-material specifications and supplier qualification for critical components (antibodies, enzymes, antigens), an approved formulation revision with controlled weighing, in-process checks, and lot release testing against panels or reference lots before the new lot is released. Keeping the new lot's genealogy, formulation revision and release data together makes it possible to compare lots and to investigate a shift when one is reported.

Laboratories then check a new lot on receipt before it is used for patient testing. CLSI EP26 describes a user protocol for evaluating whether a reagent lot change is acceptable. A drift seen across several lots may point back to a component supplier or a formulation change, which is why complaint trends should be read against the lots and component lots involved.

A worked example: three customers report slightly higher control values after switching to a new kit lot. The manufacturer compares release data for the old and new lots, traces both to their antibody and calibrator lots, finds that a new calibrator lot coincides with the shift, and decides through its nonconformance and CAPA process whether action is needed. The investigation and decision rest with people; records only make the comparison quick.

Related concepts: reagent lot traceability, reagent stability, CAPA and SPC. Sources: CLSI EP26, FDA QMSR.